Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.43 |
| ▸ | RAB9A | P51151 | 6/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 4/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.37 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.37 |
| ▸ | ITGAV | P06756 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6284064 | 1.00 | ALDH1A1 (0.43) | ALDH1A1RAB9AKDM4EMAPTHPGD | |
| SCHEMBL6284069 | 1.00 | ALDH1A1 (0.43) | ALDH1A1RAB9AKDM4EMAPTHPGD | |
| SCHEMBL4471849 | 0.95 | ALDH1A1 (0.45) | ALDH1A1RAB9AKDM4EMAPTHPGD | |
| SCHEMBL4471855 | 0.95 | ALDH1A1 (0.45) | ALDH1A1RAB9AKDM4EMAPTHPGD | |
| SCHEMBL9155120 | 0.74 | ALDH1A1 (0.49) | ALDH1A1RAB9AKDM4EMAPTHPGD | |
| SCHEMBL9155121 | 0.74 | ALDH1A1 (0.49) | ALDH1A1RAB9AKDM4EMAPTHPGD | |
| SCHEMBL6282254 | 0.74 | ALDH1A1 (0.42) | ALDH1A1RAB9AKDM4EMAPTHPGD | |
| SCHEMBL6282256 | 0.74 | ALDH1A1 (0.42) | ALDH1A1RAB9AKDM4EMAPTHPGD | |
| SCHEMBL9157162 | 0.73 | ALDH1A1 (0.47) | ALDH1A1RAB9AKDM4EMAPTHPGD | |
| SCHEMBL9157167 | 0.73 | ALDH1A1 (0.47) | ALDH1A1RAB9AKDM4EMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6858743-B2 | Method for the production of 2-coumarone and substituted 2-coumarones | DSM FINE CHEMICALS AUSTRIA NFG GMBH & CO, KG (AT) | 2005-02-22 | — | — | US | claimed |
| EP-1449838-A1 | Process for the preparation of 2-coumaranone and substituted 2-coumaranones | DSM Fine Chemicals Austria Nfg GmbH & Co KG (AT) | 2004-08-25 | — | — | EP | claimed |
| EP-1286981-B1 | METHOD FOR THE PRODUCTION OF 2- COUMARONE AND SUBSTITUTED 2-COUMARONES | DSM FINE CHEM AUSTRIA GMBH (AT) | 2004-08-04 | — | — | EP | claimed |
| US-20030171601-A1 | Method for the production of 2-coumarone and substituted 2-coumarones | DSM FINE CHEMICALS AUSTRIA NFG GMBH & COKG (AT) | 2003-09-11 | — | — | US | claimed |
| EP-1286981-A1 | METHOD FOR THE PRODUCTION OF 2- COUMARONE AND SUBSTITUTED 2-COUMARONES | DSM Fine Chemicals Austria Nfg GmbH & Co KG (AT) | 2003-03-05 | — | — | EP | claimed |
| WO-2001094329-A1 | METHOD FOR THE PRODUCTION OF 2- COUMARONE AND SUBSTITUTED 2-COUMARONES | DSM FINE CHEMICALS AUSTRIA NFG GMBH & CO KG (AT) | 2001-12-13 | — | — | WO | claimed |
| EP-0818451-B1 | Process for the preparation of the enollactone of the 2-oxocyclohexylidene acetic acid and use for the preparation of the 2-coumaranone | CLARIANT FRANCE SA (FR) | 2001-06-13 | — | — | EP | claimed |
| US-20210253562-A1 | ACYLSUFONAMIDE COMPOUNDS USEFUL AS EP3 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2021-08-19 | — | — | US | disclosed |
| US-20210253562-A1 | ACYLSUFONAMIDE COMPOUNDS USEFUL AS EP3 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2021-08-19 | — | — | US | disclosed |
| WO-2020008317-A1 | ACYLSUFONAMIDE COMPOUNDS USEFUL AS EP3 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2020-01-09 | — | — | WO | disclosed |
| EP-1656141-B1 | TREATMENT FOR ALZHEIMER S DISEASE AND RELATED CONDITIONS | MERCK SHARP & DOHME (GB) | 2010-04-14 | — | — | EP | disclosed |
| US-20080153817-A1 | Treatment for Alzheimer's Disease and Related Conditions | MERCK SHARP & DOHME LTD. (GB) | 2008-06-26 | — | — | US | disclosed |
| US-20080153817-A1 | Treatment for Alzheimer's Disease and Related Conditions | MERCK SHARP & DOHME LTD. (GB) | 2008-06-26 | — | — | US | disclosed |
| US-20030171601-A1 | Method for the production of 2-coumarone and substituted 2-coumarones | DSM FINE CHEMICALS AUSTRIA NFG GMBH & COKG (AT) | 2003-09-11 | — | — | US | disclosed |
| CN-1434815-A | Method for the production of 2-coumarone and substituted 2-coumarones | DSM FINE CHEM AUSTRIA GMBH (AT) | 2003-08-06 | — | — | CN | disclosed |
| EP-1286981-A1 | METHOD FOR THE PRODUCTION OF 2- COUMARONE AND SUBSTITUTED 2-COUMARONES | DSM Fine Chemicals Austria Nfg GmbH & Co KG (AT) | 2003-03-05 | — | — | EP | disclosed |
| EP-1286981-A1 | METHOD FOR THE PRODUCTION OF 2- COUMARONE AND SUBSTITUTED 2-COUMARONES | DSM Fine Chemicals Austria Nfg GmbH & Co KG (AT) | 2003-03-05 | — | — | EP | disclosed |
| WO-2001094329-A8 | METHOD FOR THE PRODUCTION OF 2- COUMARONE AND SUBSTITUTED 2-COUMARONES | DSM FINE CHEM AUSTRIA GMBH (AT) | 2003-02-13 | — | — | WO | disclosed |
| WO-2001094329-A1 | METHOD FOR THE PRODUCTION OF 2- COUMARONE AND SUBSTITUTED 2-COUMARONES | DSM FINE CHEMICALS AUSTRIA NFG GMBH & CO KG (AT) | 2001-12-13 | — | — | WO | disclosed |
| WO-2001094329-A1 | METHOD FOR THE PRODUCTION OF 2- COUMARONE AND SUBSTITUTED 2-COUMARONES | DSM FINE CHEMICALS AUSTRIA NFG GMBH & CO KG (AT) | 2001-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153817-A1 | Treatment for Alzheimer's Disease and Related Conditions | PSEN1, PSEN2, APP | ALDH1A1 1194/4885RAB9A 3078/4885KDM4E 4568/4885 |
| US-20030171601-A1 | Method for the production of 2-coumarone and substituted 2-coumarones | HAO2, HACL2, HAAO | ALDH1A1 276/4885RAB9A 3317/4885KDM4E 1370/4885 |
| US-20210253562-A1 | ACYLSUFONAMIDE COMPOUNDS USEFUL AS EP3 RECEPTOR ANTAGONISTS | PTGER3, FFAR3, PTGES3 | ALDH1A1 3778/4885RAB9A 3186/4885KDM4E 2587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.